Evidence map›Paper›PMID 42189295›Full record

ReviewSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026

Comparing clinical practice guidelines on the prevention and management of chemotherapy-induced hand-foot syndrome.

Dominic Sferrazza, Natalie Wang, Maryam Lustberg, Michael Jefford, Florian Scotte, Julie Ryan Wolf, Corina van den Hurk, Dominic C W Chan, Terry L Ng, Katarzyna J Jerzak and 8 more

Abstract readComparative StudyReview
PubMed Publisher
In one paragraph

Review in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Dominic SferrazzaFaculty of Health Sciences, Queen's University, Kingston, ON, Canada.
Natalie WangFaculty of Health Sciences, Queen's University, Kingston, ON, Canada.
Maryam LustbergDepartment of Medicine, School of Medicine, Yale University, New Haven, CT, USA.
Michael JeffordCentre for Health Services Research, Australian Cancer Survivorship Centre, and Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Florian ScotteInterdisciplinary Patient Pathway Department, Gustave Roussy, Villejuif, France.
Julie Ryan WolfDepartment of Dermatology, University of Rochester Medical Centre, Rochester, NY, USA.
Corina van den HurkCatharina Hospital, Eindhoven, Netherlands.
Dominic C W ChanDepartment of Oncology, Princess Margaret Hospital, Kowloon West Cluster, Hong Kong, S.A.R., China.
Terry L NgDivision of Medical Oncology, Department of Medicine, University of Ottawa, Ottawa, Canada.
Katarzyna J JerzakDivision of Medical Oncology, Department of Medicine, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
Raymond J ChanCaring Futures Institute, College of Nursing and Health Sciences, Flinders University, Adelaide, SA, Australia.
Alexandre ChanDepartment of Clinical Pharmacy Practice, School of Pharmacy & Pharmaceutical Sciences, University of California, Irvine, Irvine, CA, USA.
Muna AlkhaifiDepartment of Family and Community Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Shing Fung LeeDepartment of Radiation Oncology, National University Cancer Institute, National University Hospital, Singapore, Singapore.
Adrian W ChanDepartment of Radiation Oncology, BC Cancer-Vancouver, Vancouver, Canada.
Howard J LimDepartment of Medical Oncology, BC Cancer-Vancouver, Vancouver, Canada.
Edward ChowDepartment of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
Henry C Y WongDepartment of Oncology, Princess Margaret Hospital, Kowloon West Cluster, Hong Kong, S.A.R., China. henrywong3011@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

INTRODUCTION/

backgroundHand-foot syndrome (HFS) is a common side effect of chemotherapy drugs such as 5-fluorouracil and capecitabine, impairing daily function and quality of life. This study aimed to compare international clinical guidelines regarding assessment and management of HFS to identify areas of consensus and divergence and evidence gaps.

methodsGuidelines were identified through PubMed (from inception to February 2025), with a supplementary search on Google. Only the most recent versions of English guidelines were included. Data extraction focused on the guideline methodology and recommendations on the prevention, assessment, and management of HFS. Each guideline was critically appraised using the AGREE II checklist.

resultsSix guidelines were identified authored by the following cancer agencies: British Columbia Cancer (BCC), European Society of Medical Oncology (ESMO), Cancer Institute NSW (eviQ), Oncology Nursing Society (ONS), United Kingdom Oncology Nursing Society and Acute Oncology (UKONS AO), and United Kingdom North Cancer Alliance (UKNCA). Regarding prevention, five of six guidelines (83%) advised avoiding chemical and physical stressors to the hands and feet and using alcohol-free moisturizer. Only ESMO, BCC, and eviQ recommended oral celecoxib to prevent capecitabine-induced HFS. ESMO and ONS recommended cooling procedures to prevent taxane-induced HFS. Likewise, BCC and eviQ recommend cooling procedures for all agents. All guidelines except ONS recommended dose suspension with grade 2 or 3 HFS and continuation when resolved or improved. ESMO and BCC recommended topical corticosteroids for grade 1 HFS, ESMO for grade 2 or 3, and eviQ for prophylactic use. Finally, BCC and ESMO suggested to consider oral dexamethasone for PEGylated doxorubicin-induced HFS.

conclusionWhile general skin care and dose modification guideline recommendations were consistent, pharmacological recommendations varied. Guidelines are key for healthcare professionals in supporting patients with HFS. Therefore, regular updates with emerging evidence for interventions such as topical diclofenac are needed to ensure the quality of care.

Indexed as

Antineoplastic AgentsHand-Foot SyndromePractice Guidelines as TopicHumansNeoplasmsQuality of LifeAntineoplastic AgentsChemotherapyGuidelinesHand-foot syndrome

Identifiers

PMID42189295

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.